New way to test life-threatening reaction to anesthetic

By Admin

26 Feb, 2026

Introduction

Researchers from the University of Queensland have developed a less invasive method to test for a potentially life-threatening reaction to anesthetic. The groundbreaking study, published in the Anesthesiology, offers new hope for safer and more comfortable diagnostic procedures.

This advancement focuses on detecting susceptibility to malignant hyperthermia (MH), a rare but dangerous reaction to certain anesthetic drugs.

Understanding Malignant Hyperthermia (MH)

Malignant hyperthermia is a genetic condition that can be triggered when susceptible individuals are exposed to specific anesthetics. The reaction can cause:

• Severe muscle rigidity

• Dangerously high body temperature

• Rapid heart rate

• Acid build-up in the blood

If not treated immediately, MH can be fatal. Even when patients survive, they may suffer permanent neurological damage.

MH was first recognized in the 1960s by Michael Denborough in Melbourne after several members of the same family died following general anesthesia. Since then, medical science has worked to better understand and diagnose this condition.

The Challenge with Current Testing

According to Professor Bradley Launikonis from UQ’s School of Biomedical Sciences, susceptibility to MH is genetic. Individuals with a family history must undergo testing before receiving anesthesia.

Currently, the only accurate method involves an invasive muscle biopsy. This procedure:

• Requires a 10-centimeter incision in the thigh

• Causes significant discomfort and scarring

• Is expensive and time-consuming

• Cannot be performed on children

• Requires several days of recovery

In Australia alone, around 10 people each week undergo this invasive test across three MH Diagnostic Units.

Although genetic blood testing exists, it carries a high risk of false negatives due to the many possible mutations linked to MH.

The Breakthrough: Calcium Wave Frequency Assay

The newly developed diagnostic method, called the Calcium Wave Frequency Assay, may dramatically change how MH is detected.

This test requires only a single muscle fiber—approximately 1,000 times less muscle tissue than the current biopsy method.

Researchers hope that in the future, the test can be performed using a minimally invasive needle biopsy instead of open surgery. This would:

• Reduce pain and scarring

• Lower costs

• Shorten recovery time

• Make testing accessible to children

Professor Launikonis also noted that this innovation may have broader applications in diagnosing other muscle disorders, including muscular dystrophy.

Why Early Detection Matters

Although MH is rare, anesthetists must know whether a patient is susceptible before surgery. Special precautions can then be taken to avoid triggering agents.

If an MH reaction occurs during surgery, a muscle relaxant drug can be administered to control the crisis. However, prevention remains critical because delayed intervention can lead to fatal outcomes or permanent damage.

The Next Step

The next stage for this promising diagnostic approach is full clinical validation. Once validated, the Calcium Wave Frequency Assay could replace invasive biopsies and significantly improve patient safety and comfort worldwide.

This innovation marks a major advancement in anesthetic safety, offering a safer, faster, and less invasive way to detect a life-threatening reaction before it occurs.